Investigators

IMV Research Spotlight

Virology Education

Virology Links

Ways to Give

Contact Us

Lectures, Seminars, Meetings & Symposia

News

UMN Virology Timeline

Mark R. Schleiss

Professor

Pediatrics, Medical School

Email: schleiss@umn.edu
Phone: (612) 624-1966

Education

M.D., Oregon Health Sciences University

Research Interests

Cytomegalovirus

Selected Recent Publications

• Schleiss MR, Jensen NJ. Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection. J Virol Methods. 2003;108(1):59-65.
• Schleiss MR, Bourne N, Bravo FJ, et al. Quantitative-competitive PCR monitoring of viral load following experimental guinea pig cytomegalovirus infection. J Virol Methods. 2003;108(1):103-10.
• Schleiss MR. Vertically transmitted herpesvirus infections. Herpes. 2003;10(1):4-11.
• Xanthakos SA, Schleiss MR. Glycoprotein B genotyping of cytomegalovirus strains isolated in a pediatric population. Pediatr Infect Dis J. 2003;22(5):462-3.
• Haggerty SM, Schleiss MR. A novel CC-chemokine homolog encoded by guinea pig cytomegalovirus. Virus Genes. 2002;25(3):271-9.
• Penfold M, Miao Z, Wang Y, Haggerty S, Schleiss MR. A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1. Virology. 2003;316(2):202-12.
• Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis. 2003;188(12):1868-74.
• McGregor A, Schleiss MR. Herpesvirus genome mutagenesis by transposon-mediated strategies. Methods Mol Biol. 2004;256:281-302.
• McGregor A, Liu F, Schleiss MR. Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone. Virus Res. 2004;101(2):101-8.
• Schleiss MR, Bourne N, Stroup G, et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis. 2004;189(8):1374-81.
• McGregor A, Liu F, Schleiss MR. Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). J Virol. 2004;78(18):9872-89.
• Blackman SC , Lurain NS , Witte DP, Filipovich AH, Groen P, Schleiss MR. Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol. 2004;26(9):601-5.
• Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther. 2004;2(3):389-403.
• Schleiss MR, Bernstein DI, Passo M, Parker S, Meric C, Verdier F, Newkirk MM. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects. Vaccine. 2004;23(5):687-92.
• Schleiss MR, Bernstein DI, McVoy MA, Stroup G, Bravo F, Creasy B, McGregor A, Henninger K, Hallenberger S. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 2005;65(1):35-43.
• Schleiss MR. Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis. 2005;16(1):50-9.
• Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2005;4(3):381-406.
• Madden C, Wiley S, Schleiss MR, Benton C, Meinzen-Derr J, Greinwald J, Choo D. Audiometric, clinical and educational outcomes in a pediatric symptomatic congenital cytomegalovirus (CMV) population with sensorineural hearing loss. Int J Pediatr Otorhinolaryngol. 2005;69(9):1191-8.